{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:01Z","timestamp":1792693261405,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10147-018-1285-4","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T09:55:39Z","timestamp":1525859739000},"page":"900-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"23","author":[{"given":"Rosa","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Beth","family":"McCarville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Max R.","family":"Langham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne L.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"1285_CR1","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","volume":"361","author":"G Perilongo","year":"2009","unstructured":"Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361:1662\u20131670. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0810613","journal-title":"N Engl J Med"},{"key":"1285_CR2","first-page":"1343","volume":"36","author":"D Schweinitz von","year":"2000","unstructured":"von Schweinitz D (2000) Identification of risk groups in hepatoblastoma\u2014another step in optimising therapy. Eur J Cancer Oxf Engl 1990 36:1343\u20131346","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1285_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ejca.2005.02.004","volume":"41","author":"P Czauderna","year":"2005","unstructured":"Czauderna P, Otte JB, Aronson DC et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era\u2014recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer Oxf Engl 1990 41:1031\u20131036. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2005.02.004","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1285_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","volume":"18","author":"RL Meyers","year":"2017","unstructured":"Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. Lancet Oncol 18:122\u2013131. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30598-8","journal-title":"Lancet Oncol"},{"key":"1285_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejca.2007.11.022","volume":"44","author":"M Ioris De","year":"2008","unstructured":"De Ioris M, Brugieres L, Zimmermann A et al (2008) Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer Oxf Engl 1990 44:545\u2013550. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2007.11.022","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1285_CR6","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.1997.15.3.1190","volume":"15","author":"JM Tornout Van","year":"1997","unstructured":"Van Tornout JM, Buckley JD, Quinn JJ et al (1997) Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children\u2019s Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol 15:1190\u20131197","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1285_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jpedsurg.2009.10.023","volume":"45","author":"HN Lovvorn","year":"2010","unstructured":"Lovvorn HN, Ayers D, Zhao Z et al (2010) Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics. J Pediatr Surg 45:121\u2013128. \n                    https:\/\/doi.org\/10.1016\/j.jpedsurg.2009.10.023\n                    \n                   (discussion 129)","journal-title":"J Pediatr Surg"},{"key":"1285_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/pbc.23069","volume":"57","author":"KN Koh","year":"2011","unstructured":"Koh KN, Park M, Kim BE et al (2011) Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer 57:554\u2013560. \n                    https:\/\/doi.org\/10.1002\/pbc.23069","journal-title":"Pediatr Blood Cancer"},{"key":"1285_CR9","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","volume":"28","author":"J Zsiros","year":"2010","unstructured":"Zsiros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584\u20132590. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.22.4857","journal-title":"J Clin Oncol"},{"key":"1285_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","volume":"14","author":"J Zsiros","year":"2013","unstructured":"Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14:834\u2013842. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70272-9","journal-title":"Lancet Oncol"},{"key":"1285_CR11","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1002\/cncr.30591","volume":"123","author":"HM Katzenstein","year":"2017","unstructured":"Katzenstein HM, Furman WL, Malogolowkin MH et al (2017) Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children\u2019s Oncology Group AHEP0731 study committee: vincristine\/irinotecan in hepatoblastoma. Cancer 123:2360\u20132367. \n                    https:\/\/doi.org\/10.1002\/cncr.30591","journal-title":"Cancer"},{"key":"1285_CR12","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1200\/JCO.2005.02.6013","volume":"24","author":"MH Malogolowkin","year":"2006","unstructured":"Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol Off J Am Soc Clin Oncol 24:2879\u20132884. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.02.6013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1285_CR13","doi-asserted-by":"crossref","unstructured":"Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) AJCC Cancer Staging Manual. Springer, Chicago","DOI":"10.1007\/978-3-319-40618-3"},{"key":"1285_CR14","first-page":"75","volume":"20","author":"AJ Naus","year":"1982","unstructured":"Naus AJ, Borst A, Kuppens PS (1982) Determination of n-dimensional reference ellipsoids using patient data. J Clin Chem Clin Biochem Z F\u00fcr Klin Chem Klin Biochem 20:75\u201380","journal-title":"J Clin Chem Clin Biochem Z F\u00fcr Klin Chem Klin Biochem"},{"key":"1285_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1285_CR16","unstructured":"(2011) Base Sas 9.3 procedures guide. Sas Institute, Cary"},{"key":"1285_CR17","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1200\/JCO.2002.07.400","volume":"20","author":"HM Katzenstein","year":"2002","unstructured":"Katzenstein HM, London WB, Douglass EC et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol Off J Am Soc Clin Oncol 20:3438\u20133444","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1285_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.1993.11.1.96","volume":"11","author":"EC Douglass","year":"1993","unstructured":"Douglass EC, Reynolds M, Finegold M et al (1993) Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 11:96\u201399","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1285_CR19","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","volume":"18","author":"JA Ortega","year":"2000","unstructured":"Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children\u2019s Cancer Group and the Pediatric Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 18:2665\u20132675","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1285_CR20","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1002\/cncr.24667","volume":"115","author":"HM Katzenstein","year":"2009","unstructured":"Katzenstein HM, Chang KW, Krailo M et al (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children\u2019s Oncology Group. Cancer 115:5828\u20135835. \n                    https:\/\/doi.org\/10.1002\/cncr.24667","journal-title":"Cancer"},{"key":"1285_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/08880010590921441","volume":"22","author":"M Casanova","year":"2005","unstructured":"Casanova M, Massimino M, Ferrari A et al (2005) Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. Pediatr Hematol Oncol 22:189\u2013198. \n                    https:\/\/doi.org\/10.1080\/08880010590921441","journal-title":"Pediatr Hematol Oncol"},{"key":"1285_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/08880019809167228","volume":"15","author":"ME Blohm","year":"1998","unstructured":"Blohm ME, Vesterling-H\u00f6rner D, Calaminus G et al (1998) Alpha 1-fetoprotein (AFP) reference values in infants up to 2\u00a0years of age. Pediatr Hematol Oncol 15:135\u2013142","journal-title":"Pediatr Hematol Oncol"},{"key":"1285_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/1097-0142(19820901)50:5<821::AID-CNCR2820500502>3.0.CO;2-K","volume":"50","author":"AE Evans","year":"1982","unstructured":"Evans AE, Land VJ, Newton WA, et al (1982) Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer 50:821\u2013826. https:\/\/doi.org\/10.1002\/1097-0142(19820901)50:5<821::AID-CNCR2820500502>3.0.CO;2-K","journal-title":"Cancer"},{"key":"1285_CR24","first-page":"1243","volume":"33","author":"D Schweinitz von","year":"1997","unstructured":"von Schweinitz D, Byrd DJ, Hecker H et al (1997) Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer Oxf Engl 1990 33:1243\u20131249","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1285_CR25","first-page":"1418","volume":"36","author":"J Brown","year":"2000","unstructured":"Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblastoma\u2014results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer Oxf Engl 1990 36:1418\u20131425","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"1285_CR26","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","volume":"18","author":"J Pritchard","year":"2000","unstructured":"Pritchard J, Brown J, Shafford E et al (2000) Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach\u2014results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol Off J Am Soc Clin Oncol 18:3819\u20133828","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1285_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jpedsurg.2013.03.019","volume":"48","author":"AJ Murphy","year":"2013","unstructured":"Murphy AJ, Ayers GD, Hilmes MA et al (2013) Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy. J Pediatr Surg 48:1239\u20131248. \n                    https:\/\/doi.org\/10.1016\/j.jpedsurg.2013.03.019","journal-title":"J Pediatr Surg"},{"key":"1285_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/BF02306083","volume":"3","author":"I Medary","year":"1996","unstructured":"Medary I, Aronson D, Cheung NK et al (1996) Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. Ann Surg Oncol 3:521\u2013525","journal-title":"Ann Surg Oncol"},{"key":"1285_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/bjc.1989.115","volume":"59","author":"A Muraoka","year":"1989","unstructured":"Muraoka A, Tokiwa T, Sato J (1989) Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro. Br J Cancer 59:569\u2013572","journal-title":"Br J Cancer"},{"key":"1285_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/pbc.24038","volume":"59","author":"R Venkatramani","year":"2012","unstructured":"Venkatramani R, Wang L, Malvar J et al (2012) Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer 59:493\u2013498. \n                    https:\/\/doi.org\/10.1002\/pbc.24038","journal-title":"Pediatr Blood Cancer"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/pbc.10376","volume":"42","author":"JB Otte","year":"2004","unstructured":"Otte JB, Pritchard J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74\u201383. \n                    https:\/\/doi.org\/10.1002\/pbc.10376","journal-title":"Pediatr Blood Cancer"},{"key":"1285_CR32","volume-title":"SEER cancer statistics review, 1975\u20132009","author":"N Howlander","year":"2011","unstructured":"Howlander N, Noone A, Krapcho M et al (2011) SEER cancer statistics review, 1975\u20132009. National Cancer Institute, Bethesda"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1285-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1285-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1285-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:44:04Z","timestamp":1581961444000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1285-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1285-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]},"assertion":[{"value":"19 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}